Coherus Biosciences Share Price Today
(NASDAQ: CHRS)

Name: Coherus Biosciences Share Price Today (NASDAQ: CHRS) - Coherus Biosciences Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Coherus Biosciences share price is $1.03 & ₹89.58 as on 6 Mar 2025, 2.30 'hrs' IST

$1.03

▲

-0.02

(-1.9%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Coherus Biosciences share price in Dollar and Rupees. Guide to invest in Coherus Biosciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Coherus Biosciences, along with analyst recommendations, forecasts, and comprehensive financials.

Coherus Biosciences share price movements

Today's Low: $1.01
Today's High: $1.08
$1.03
1.94%
Downside
Day's Volatility :6.48%
Upside
4.63%
52 Weeks Low: $0.66
52 Weeks High: $2.64
$1.03
35.89%
Downside
52 Weeks Volatility :74.99%
Upside
60.98%

Coherus Biosciences (CHRS) Returns

Period	Coherus Biosciences Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-30.46%	2.1%	0.0%
6 Months	-20.45%	-4.1%	0.0%
1 Year	-52.49%	2.2%	0.0%
3 Years	-90.96%	11.8%	-11.6%

Coherus Biosciences (CHRS) Key Statistics

in dollars & INR

Previous Close	$1.05
Open	$1.05
Today's High	$1.08
Today's Low	$1.01
Market Capitalization	$116.5M
Today's Volume	$193.1K
52 Week High	$2.64
52 Week Low	$0.6603
Revenue TTM	$304.3M
EBITDA	$-116.9M
Earnings Per Share (EPS)	$-0.09
Profit Margin	-0.15%
Quarterly Earnings Growth YOY	-0.75%
Return On Equity TTM	-1657.06%

How to invest in Coherus Biosciences Stock (CHRS) from India?

It is very easy for Indian residents to invest directly in Coherus Biosciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Coherus Biosciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Coherus Biosciences or CHRS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Coherus Biosciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Coherus Biosciences shares which would translate to 0.844 fractional shares of Coherus Biosciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Coherus Biosciences, in just a few clicks!

Returns in Coherus Biosciences (CHRS) for Indian investors in Rupees

The Coherus Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Coherus Biosciences investment value today

Current value as on today

₹51,569

Returns

₹48,431

(-48.43%)

Returns from Coherus Biosciences Stock

₹53,394 (-53.39%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Coherus Biosciences (CHRS)

11%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Coherus Biosciences Stock from India on INDmoney has increased by 11% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Coherus Biosciences

Vanguard Group Inc
9.63%
BlackRock Inc
9.56%
Point72 Asset Management, L.P.
4.56%
Rubric Capital Management LP
4.54%
TANG CAPITAL MANAGEMENT LLC
3.15%
Kohlberg Kravis Roberts & Co LP
2.62%

Analyst Recommendation on Coherus Biosciences

Buy

81%Buy

18%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Coherus Biosciences(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Coherus Biosciences Stock (CHRS)

What analysts predicted

Upside of 472.82%

Target:

$5.90

Current:

$1.03

Insights on Coherus Biosciences Stock (Ticker Symbol: CHRS)

Price Movement
In the last 3 years, CHRS stock has moved down by -91.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 64.97M → 70.77M (in $), with an average increase of 8.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -12.92M → -10.75M (in $), with an average increase of 20.2% per quarter
CHRS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 114.1%
CHRS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 138.8%
Price to Sales
ForCHRS every $1 of sales, investors are willing to pay $0.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

CHRS Coherus Biosciences Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.6M	↑ 0.0%
Net Income	$-209.3M	↓ 12.11%
Net Profit Margin	-13.5K%	↑ 1852.9%

	FY19	Y/Y Change
Revenue	$356.1M	↑ 22783.74%
Net Income	$89.8M	↓ 142.91%
Net Profit Margin	25.23%	↑ 13478.89%

	FY20	Y/Y Change
Revenue	$475.8M	↑ 33.63%
Net Income	$132.2M	↑ 47.21%
Net Profit Margin	27.79%	↑ 2.56%

	FY21	Y/Y Change
Revenue	$326.6M	↓ 31.37%
Net Income	$-306.3M	↓ 331.63%
Net Profit Margin	-93.81%	↓ 121.6%

	FY22	Y/Y Change
Revenue	$211.0M	↓ 35.37%
Net Income	$-326.6M	↑ 6.63%
Net Profit Margin	-154.77%	↓ 60.96%

	FY23	Y/Y Change
Revenue	$257.2M	↑ 21.89%
Net Income	$-237.9M	↓ 27.17%
Net Profit Margin	-92.48%	↑ 62.29%

	Q2 FY23	Q/Q Change
Revenue	$58.7M	↑ 81.02%
Net Income	$-42.9M	↓ 42.67%
Net Profit Margin	-73.01%	↑ 157.54%

	Q3 FY23	Q/Q Change
Revenue	$74.6M	↑ 27.0%
Net Income	$-39.6M	↓ 7.53%
Net Profit Margin	-53.16%	↑ 19.85%

	Q4 FY23	Q/Q Change
Revenue	$91.5M	↑ 22.74%
Net Income	$-79.7M	↑ 100.94%
Net Profit Margin	-87.03%	↓ 33.87%

	Q1 FY24	Q/Q Change
Revenue	$77.1M	↓ 15.8%
Net Income	$102.9M	↓ 229.15%
Net Profit Margin	133.49%	↑ 220.52%

	Q2 FY24	Q/Q Change
Revenue	$65.0M	↓ 15.68%
Net Income	$-12.9M	↓ 112.56%
Net Profit Margin	-19.88%	↓ 153.37%

	Q3 FY24	Q/Q Change
Revenue	$70.8M	↑ 8.92%
Net Income	$-10.8M	↓ 16.79%
Net Profit Margin	-15.19%	↑ 4.69%

	FY18	Y/Y Change
Profit	$1.6M	↑ 0.0%

	FY19	Y/Y Change
Profit	$339.0M	↑ 21686.18%

	FY20	Y/Y Change
Profit	$438.2M	↑ 29.25%

	FY21	Y/Y Change
Profit	$269.0M	↓ 38.62%

	FY22	Y/Y Change
Profit	$141.0M	↓ 47.59%

	FY23	Y/Y Change
Profit	$94.5M	↓ 32.99%

	Q2 FY23	Q/Q Change
Profit	$33.9M	↑ 117.63%

	Q3 FY23	Q/Q Change
Profit	$41.9M	↑ 23.61%

	Q4 FY23	Q/Q Change
Profit	$5.9M	↓ 85.92%

	Q1 FY24	Q/Q Change
Profit	$41.0M	↑ 595.11%

	Q2 FY24	Q/Q Change
Profit	$35.4M	↓ 13.54%

	Q3 FY24	Q/Q Change
Profit	$50.0M	↑ 41.24%

	FY18	Y/Y Change
Operating Cash Flow	$-159.3M	↓ 20.48%
Investing Cash Flow	$-1.2M	↓ 73.1%
Financing Cash Flow	$105.4M	↓ 49.02%

	FY19	Y/Y Change
Operating Cash Flow	$28.4M	↓ 117.8%
Investing Cash Flow	$-12.7M	↑ 971.72%
Financing Cash Flow	$89.4M	↓ 15.23%

	FY20	Y/Y Change
Operating Cash Flow	$154.1M	↑ 443.63%
Investing Cash Flow	$-14.4M	↑ 13.11%
Financing Cash Flow	$223.9M	↑ 150.58%

	FY21	Y/Y Change
Operating Cash Flow	$-37.4M	↓ 124.28%
Investing Cash Flow	$-138.4M	↑ 861.11%
Financing Cash Flow	$51.9M	↓ 76.83%

	FY22	Y/Y Change
Operating Cash Flow	$-241.1M	↑ 544.17%
Investing Cash Flow	$-166.9M	↑ 20.55%
Financing Cash Flow	$54.3M	↑ 4.72%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-38.9M	↓ 43.38%
Investing Cash Flow	$41.4M	↑ 136.02%
Financing Cash Flow	$54.3M	↑ 1328.1%

Coherus Biosciences Technicals Summary

Sell

Neutral

Buy

Coherus Biosciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Coherus Biosciences (CHRS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Coherus Biosciences Inc	-5.41%	-20.45%	-52.49%	-90.96%	-94.11%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Coherus Biosciences Inc	NA	NA	0.0	-0.86	-16.57	-0.14	NA	-0.76
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Coherus Biosciences Inc	Buy	$116.5M	-94.11%	NA	-0.15%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Coherus Biosciences

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Organization	Coherus Biosciences
Employees	235
CEO	Mr. Dennis M. Lanfear
Industry	Health Technology

Management People of Coherus Biosciences

Name	Title
Mr. Dennis M. Lanfear	Chairman, President & CEO
Mr. Bryan J. McMichael	Chief Financial Officer
Mr. Paul Reider	Chief Commercial Officer
Mr. Richard L. Hameister	Chief Technical Officer
Ms. Jodi Sievers	Vice President of Investor Relations & Corporate Communications
Mr. Andy Rittenberg	Executive Vice President of General Counsel
Mr. Scott Saywell	Executive Vice President of Corporate Development
Ms. Rebecca Sunshine	Chief Human Resources Officer
Mr. Michael Chen	Senior Vice President of Commercial Analytics & Trade
Dr. Theresa M. Lavallee Ph.D.	Chief Development Officer & Chairman of Scientific Advisory Board

Important FAQs about investing in CHRS Stock from India :

What is Coherus Biosciences share price today?

Coherus Biosciences share price today stands at $1.03, Open: $1.05 ; Previous Close: $1.05 ; High: $1.08 ; Low: $1.01 ; 52 Week High: $2.64 ; 52 Week Low: $0.66.

The stock opens at $1.05, after a previous close of $1.05. The stock reached a daily high of $1.08 and a low of $1.01, with a 52-week high of $2.64 and a 52-week low of $0.66.

Can Indians buy Coherus Biosciences shares?

Yes, Indians can invest in the Coherus Biosciences (CHRS) from India.

With INDmoney, you can buy Coherus Biosciences at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Coherus Biosciences at zero transaction cost.

How can I buy Coherus Biosciences shares from India?

It is very easy to buy Coherus Biosciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Coherus Biosciences (CHRS) be purchased?

Yes, you can buy fractional shares of Coherus Biosciences with INDmoney app.

What are the documents required to start investing in Coherus Biosciences stocks?

To start investing in Coherus Biosciences, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.